The independent and combined effects of RAR-, RXR-, and VDR-selective ligands on the growth of squamous cell carcinoma in vitro

Journal of Otolaryngology

Volumn 28, Issue 2, 1999, Pages 83-89

  Enepekides, Danny J ^a   Black, Martin J ^a,b   White, John H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

13 cis retinoic acid; Chemopreventive therapy; RAR selective ligands; RXR selective ligands; Squamous cell carcinoma; VDR selective ligands; Vitamin D3

Indexed keywords

BETA GALACTOSIDASE; BEXAROTENE; CALCITRIOL; ISOTRETINOIN; LIGAND; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PREVENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0032954414     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Yokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993; 328:184-194.
2. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer - larynx preservation and cancer chemoprevention. Cancer Res 1994; 53:5113-5120.
3. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6:963-968.
4. Lippman SM, Banner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12:851-873.
5. Lippman SM, Kessler JF, Meyskins FL. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987; 71:493-515.
6. Shalinsky DR, Bischoff ED, Lamph WW, et al. A noval retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous cell carcinoma xenografts in nude mice. Cancer Res 1997; 57: 162-168.
7. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 1997; 154:557-573.
8. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
9. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994; 86:140-141.
10. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 1993; 11:1216-1222.
11. Holick MF. Will 1,25 dihydroxyvitamin D3, MC903, and their analogs herald a new pharmacologic era for the treatment of psoriasis. Arch Dermatol 1989; 125:1692-1697.
12. Yu J, Papavasiliou V, Rhim J, et al. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995; 6: 101-108.
13. McElwain MC, Modzelewski RA, Yu WD, et al. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otol 1997; 18:293-298.
14. Kornfehl J, Formanek M, Temmel A, et al. Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25 [OH]2 D3) on head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 1996; 253:341-344.
15. Zavacki AM, Lehmann JM, Seol W, et al. Activation of the orphan receptor RIP14 by retinoids. Proc Natl Acad Sci US A 1997; 94:7909-7914.
16. Miller VA, Benedetti FM, Verret AL, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15:790-795.
17. Tora L, White JH, Bron C, et al. Human estrogen receptor has two independent non-acidic transactivation functions. Cell 1989; 59:477-487.
18. Hu L, Crowe DL, Rheinwald JG, et al. Abnormal expression of the retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 1991; 51:3972-3981.
19. Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54: 3580-3587.
20. Shah JP, Strong E, DeCosse JJ. Effect of retinoids on oral leukoplakia. Am J Surg 1983; 146:466-470.
21. Hong WK, Endicott J, Itri LM, et al. 13-Cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-1505.
22. Giannini F, Maestro R, Vukosavijevic T, et al. All-trans, 13-cis, and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J Cancer 1997; 70:194-200.
23. Radiation Therapy Oncology Group. RTOG 91-15: Chemoprevention trial to prevent second primary tumors with low-dose 13-cis retinoic acid in head and neck cancer. 1993.
24. Walters MR. Newly identified actions in the vitamin D endocrine system. Endocr Rev 1992; 13:719-764.
25. Apfel CM, Kamber M, Klaus M, et al. Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor. J Biol Chem 1995; 270:30765-30772.
26. 3 are differentially modified by 9-cis retinoic acid. Cancer Res 1996; 56:623-632.
27. 3-resistant variant. Endocrinology 1997; 138:4690-4698.
28. 3 and 9-cis retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997; 138:1491-1497.
29. Huang C, Ma WY, Dawson MI, et al. Blocking activator protein-1 activity, but not activating retinoic response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A 1997; 94:5826-5830.
30. 3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Oncogene 1995; 11:1853-1858.
31. Colston KW, Mackay AG, Chander S, et al. Novel vitamin D analogues suppress tumor growth in vitro. In: Norman AW, Bovillon R, Thomasset M, eds. Vitamin D: gene regulation, structure-function analysis and clinical application. Proc 8th Workshop on Vitamin D. Berlin: de Gruyter, 1991:465-466.